A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults (NCT07290036)
An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis
🩺 Plain-English Summary (8th-Grade Level)
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
Who can join: Review the eligibility criteria below.
Location: Pa0019 114 — Peoria, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (63 Sites)
Showing the first 25 of 63 sites.
- Pa0019 114 — Peoria, Arizona
- Pa0019 127 — Apple Valley, California
- Pa0019 111 — Covina, California
- Pa0019 119 — Fullerton, California
- Pa0019 117 — Riverside, California
- Pa0019 125 — San Leandro, California
- Pa0019 126 — Temecula, California
- Pa0019 141 — Upland, California
- Pa0019 120 — Whittier, California
- Pa0019 128 — Whittier, California
- Pa0019 123 — Fort Collins, Colorado
- Pa0019 143 — Ormond Beach, Florida
- Pa0019 113 — South Miami, Florida
- Pa0019 133 — Zephyrhills, Florida
- Pa0019 132 — Chicago, Illinois
- Pa0019 134 — Lansing, Michigan
- Pa0019 140 — West Long Branch, New Jersey
- Pa0019 131 — Albuquerque, New Mexico
- Pa0019 144 — Vandalia, Ohio
- Pa0019 115 — Duncansville, Pennsylvania
- Pa0019 142 — Rock Hill, South Carolina
- Pa0019 116 — Jackson, Tennessee
- Pa0019 138 — Murfreesboro, Tennessee
- Pa0019 129 — Baytown, Texas
- Pa0019 136 — Colleyville, Texas
📞 Contact the Study Coordinator
Phone: (844) 599-2273
Email: ucbcares@ucb.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Psoriatic Arthritis
- A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs — Gilbert, Arizona
- Psoriatic Arthritis D2P Screening — Philadelphia, Pennsylvania
- Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis — Dothan, Alabama
- Apremilast Pregnancy Exposure Registry — La Jolla, California
- Psorcast Mobile Study — Seattle, Washington
- A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy — Anniston, Alabama
Explore by condition: All Psoriatic Arthritis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.